Login to Your Account


Strike two for rigosertib: Onconova phase III miss in MDS wallops shares

By Randy Osborne
Staff Writer

Thursday, February 20, 2014
Not surprising but hardly well taken by investors was the second setback with Onconova Therapeutics Inc.’s intravenous (I.V.) rigosertib for higher-risk myelodysplastic syndromes (MDS), which failed to meet its primary endpoint of overall survival (OS) in the phase III trial known as ONTIME.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription